English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Phase I early‐phase clinical studies aim at investigating the safety and the underlying  dose‐toxicity  relationship of a drug or combination. While little may still be known about the compound's properties, it is crucial to consider quantitative information available from any studies that may have been conducted previously on the same drug. A meta‐analytic approach has the advantages of being able to properly account for between‐study heterogeneity, and it may be readily extended to prediction or shrinkage applications. Here we propose a simple and robust two‐stage approach for the estimation of maximum tolerated dose(s) utilizing penalized logistic regression and Bayesian random‐effects meta‐analysis methodology. Implementation is facilitated using standard  R  packages. The properties of the proposed methods are investigated in Monte Carlo simulations. The investigations are motivated and illustrated by two examples from oncology.

A straightforward meta‐analysis approach for oncology phase I dose‐finding studies